These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 22133206)

  • 41. Changes in Serum Intact Fibroblast Growth Factor 23 Concentrations From Midlife to Late Life and Their Predictors in the Community: The ARIC Study.
    Ishigami J; Honda Y; Karger AB; Coresh J; Selvin E; Lutsey PL; Matsushita K
    Mayo Clin Proc Innov Qual Outcomes; 2022 Jun; 6(3):209-217. PubMed ID: 35517245
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pathophysiological Implications of Imbalances in Fibroblast Growth Factor 23 in the Development of Diabetes.
    Donate-Correa J; Martín-Núñez E; González-Luis A; Ferri CM; Luis-Rodríguez D; Tagua VG; Mora-Fernández C; Navarro-González JF
    J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34208131
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Favourable serum calcification propensity with intraperitoneal as compared with subcutaneous insulin administration in type 1 diabetes.
    van Dijk PR; Waanders F; Pasch A; Logtenberg SJJ; Vriesendorp T; Groenier KH; Hillebrands JL; Kleefstra N; Gans ROB; van Goor H; Bilo HJG
    Ther Adv Endocrinol Metab; 2020; 11():2042018820908456. PubMed ID: 32166012
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Insulin suppresses the production of fibroblast growth factor 23 (FGF23).
    Bär L; Feger M; Fajol A; Klotz LO; Zeng S; Lang F; Hocher B; Föller M
    Proc Natl Acad Sci U S A; 2018 May; 115(22):5804-5809. PubMed ID: 29760049
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Role and Potential Therapeutic Implications of the Fibroblast Growth Factors in Energy Balance and Type 2 Diabetes.
    Izaguirre M; Gil MJ; Monreal I; Montecucco F; Frühbeck G; Catalán V
    Curr Diab Rep; 2017 Jun; 17(6):43. PubMed ID: 28451950
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Elevation in fibroblast growth factor 23 and its value for identifying subclinical atherosclerosis in first-degree relatives of patients with diabetes.
    Hu X; Ma X; Luo Y; Xu Y; Xiong Q; Pan X; Bao Y; Jia W
    Sci Rep; 2016 Oct; 6():34696. PubMed ID: 27698482
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High Fibroblast Growth Factor 23 Levels Associated With Low Hemoglobin Levels in Patients With Chronic Kidney Disease Stages 3 and 4.
    Tsai MH; Leu JG; Fang YW; Liou HH
    Medicine (Baltimore); 2016 Mar; 95(11):e3049. PubMed ID: 26986127
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Iron and obesity status-associated insulin resistance influence circulating fibroblast-growth factor-23 concentrations.
    Fernández-Real JM; Puig J; Serrano M; Sabater M; Rubió A; Moreno-Navarrete JM; Fontan M; Casamitjana R; Xifra G; Ortega FJ; Salvador J; Frühbeck G; Ricart W
    PLoS One; 2013; 8(3):e58961. PubMed ID: 23555610
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The chicken or the egg: PHEX, FGF23 and SIBLINGs unscrambled.
    Rowe PS
    Cell Biochem Funct; 2012 Jul; 30(5):355-75. PubMed ID: 22573484
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.
    Rowe PS
    Crit Rev Eukaryot Gene Expr; 2012; 22(1):61-86. PubMed ID: 22339660
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro reversal of hyperglycemia normalizes insulin action in fat cells from type 2 diabetes patients: is cellular insulin resistance caused by glucotoxicity in vivo?
    Burén J; Lindmark S; Renström F; Eriksson JW
    Metabolism; 2003 Feb; 52(2):239-45. PubMed ID: 12601640
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acute hyperinsulinemia decreases plasma osteoprotegerin with diminished effect in type 2 diabetes and obesity.
    Jørgensen GM; Vind B; Nybo M; Rasmussen LM; Højlund K
    Eur J Endocrinol; 2009 Jul; 161(1):95-101. PubMed ID: 19380455
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acute hyperinsulinemia is followed by increased serum concentrations of fibroblast growth factor 23 in type 2 diabetes patients.
    Winther K; Nybo M; Vind B; Pedersen SM; Højlund K; Rasmussen LM
    Scand J Clin Lab Invest; 2012 Apr; 72(2):108-13. PubMed ID: 22133206
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acute hyperinsulinemia raises plasma interleukin-6 in both nondiabetic and type 2 diabetes mellitus subjects, and this effect is inversely associated with body mass index.
    Ruge T; Lockton JA; Renstrom F; Lystig T; Sukonina V; Svensson MK; Eriksson JW
    Metabolism; 2009 Jun; 58(6):860-6. PubMed ID: 19375766
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Clamp-Like Index: a novel and highly sensitive insulin sensitivity index to calculate hyperinsulinemic clamp glucose infusion rates from oral glucose tolerance tests in nondiabetic subjects.
    Anderwald C; Anderwald-Stadler M; Promintzer M; Prager G; Mandl M; Nowotny P; Bischof MG; Wolzt M; Ludvik B; Kästenbauer T; Pacini G; Luger A; Krebs M
    Diabetes Care; 2007 Sep; 30(9):2374-80. PubMed ID: 17595351
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glucose disposal in obese non-diabetic and diabetic type II patients. A study by indirect calorimetry and euglycemic insulin clamp.
    Golay A; Defronzo RA; Thorin D; Jequier E; Felber JP
    Diabete Metab; 1988; 14(4):443-51. PubMed ID: 3066652
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.